4.7 Article

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

Journal

ALZHEIMERS & DEMENTIA
Volume 15, Issue 10, Pages 1333-1347

Publisher

WILEY
DOI: 10.1016/j.jalz.2019.06.4950

Keywords

Alzheimer's disease; Vascular pathology; Cerebral amyloid angiopathy; GWAS; Biological pathway

Funding

  1. Fundacion bancaria La Caixa
  2. Grifols SA
  3. Fundacio ACE
  4. ISCIII (Ministry of Health, Spain)
  5. European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED project [115975]
  6. European Union/EFPIA Innovative Medicines Initiative Joint undertaking MOPEAD project [115985]
  7. ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion
  8. Fondo Europeo de Desarrollo Regional (FEDER-Una manera de Hacer Europa)
  9. Consejeria de Salud de la Junta de Andalucia [PI-0001/2017]
  10. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  11. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  12. National Institute on Aging
  13. National Institute of Biomedical Imaging and Bioengineering
  14. AbbVie
  15. Alzheimer's Association
  16. Alzheimer's Drug Discovery Foundation
  17. Araclon Biotech
  18. BioClinica, Inc.
  19. Biogen
  20. Bristol-Myers Squibb Company
  21. CereSpir, Inc.
  22. Cogstate
  23. Eisai Inc.
  24. Elan Pharmaceuticals, Inc.
  25. Eli Lilly and Company
  26. EuroImmun
  27. F. Hoffmann-La Roche Ltd
  28. Genentech, Inc.
  29. Fujirebio
  30. GE Healthcare
  31. IXICO Ltd.
  32. Janssen Alzheimer Immunotherapy Research AMP
  33. Development, LLC.
  34. Johnson AMP
  35. Johnson Pharmaceutical Research AMP
  36. Development LLC.
  37. Lumosity
  38. Lundbeck
  39. Merck Co., Inc.
  40. Meso Scale Diagnostics, LLC.
  41. NeuroRx Research
  42. Neurotrack Technologies
  43. Novartis Pharmaceuticals Corporation
  44. Pfizer Inc.
  45. Piramal Imaging
  46. Servier
  47. Takeda Pharmaceutical Company
  48. Transition Therapeutics
  49. Canadian Institutes of Health Research
  50. SMEs as part of InnoMed (Innovative Medicines in Europe) - European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5
  51. NIA Division of Neuroscience [U01-AG032984]
  52. NIA [P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, AG081220]
  53. NINDS [R01 NS080820]
  54. CurePSP Foundation
  55. Mayo Foundation
  56. Fundacion Alzheimur (Murcia)
  57. Ministerio de Educacion y Ciencia (Gobierno de Espana)
  58. Corporacion Tecnologica de Andalucia
  59. Agencia IDEA (Consejeria de Innovacion, Junta de Andalucia)
  60. Diabetes Research Laboratory
  61. Biomedical Research Foundation
  62. CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM)
  63. Kronos Life Science Laboratories
  64. National Institute on Aging (Arizona Alzheimer's Disease Center) [P30 AG19610, RO1 AG023193]
  65. Mayo Clinic Alzheimer's Disease Center [P50 AG16574]
  66. National Alzheimer's Coordinating Center [U01 AG016976]
  67. state of Arizona
  68. French National Foundation on Alzheimer's disease and related disorders
  69. LABEX (laboratory of excellence program investment for the future) DISTALZ grant
  70. Inserm
  71. Institut Pasteur de Lille
  72. Universite de Lille 2
  73. Lille University Hospital
  74. Medical Research Council [503480]
  75. Wellcome Trust [082604/2/07/Z]
  76. German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) [01GI0102, 01GI0711, 01GI0420]
  77. AGES [N01-AG12100]
  78. NHLBI [R01 HL105756]
  79. Icelandic Heart Association
  80. Erasmus Medical Center and Erasmus University
  81. NIH/NIA [U01 AG016976, U01 AG032984, U24 AG021886, R01 AG033193]
  82. Alzheimer's Association [ADGC-10-196728]
  83. Alzheimer's Research UK [503176]
  84. Illinois Department of Public Health
  85. Translational Genomics Research Institute
  86. Piramal AG
  87. Laboratorios Echevarne
  88. Araclon Biotech S.A.
  89. Trinitat Port-Carbo legacy
  90. [PI13/02434]
  91. [PI16/01861]
  92. [PI17/01474]

Ask authors/readers for more resources

Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available